Article

Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL

2025-11-13

Abstract excerpt

<h4>ABSTRACT</h4> Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improved outcomes, but acquired resistance limits their long-term efficacy. Here, we modeled the developm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fa239b21-5836-55c8-bd8a-00abc909f402
DOI: 10.1101/2025.11.12.687947

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCLDOI 10.1101/2025.11.12.687947Read

miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell LymphomaSemantic proximity Read

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.Semantic proximity Read

Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphomaSemantic proximity Read

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Semantic proximity Read

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCLSemantic proximity Read

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Semantic proximity Read

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.Semantic proximity Read

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.Semantic proximity Read

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.Semantic proximity Read

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read